Travere Therapeutics (TVTX)
NASDAQ:TVTX
Want to see TVTX full AI Analyst Report?
TVTX Stock Chart & Stats
$40.77
-$0.11(-0.58%)
At close: 4:00 PM EST
$40.77
-$0.11(-0.58%)
Day’s Range― - ―
52-Week Range$13.88 - $48.61
Previous CloseN/A
Volume140.04K
Average Volume (3M)2.05M
Market Cap
$3.97B
Enterprise Value$4.22B
Total Cash (Recent Filing)$322.80M
Total Debt (Recent Filing)$339.87M
Price to Earnings (P/E)―
Beta1.72
Next Earnings
Jul 30, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.56
Shares Outstanding92,992,905
10 Day Avg. Volume3,838,751
30 Day Avg. Volume2,049,604
Financial Highlights & Ratios
PEG Ratio1.55
Price to Book (P/B)29.69
Price to Sales (P/S)6.95
P/FCF Ratio90.22
Enterprise Value/Market Cap1.06
Enterprise Value/Revenue8.59
Enterprise Value/Gross Profit9.12
Enterprise Value/Ebitda189.76
Forecast
1Y Price Target
$53.42Price Target Upside31.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)0.29
Revenue Forecast (FY)$699.59M
Bulls Say, Bears Say
Bulls Say
Clinical Evidence And KOL SupportAnalyses tying proteinuria reduction to slower kidney decline, along with key opinion leader enthusiasm, suggest meaningful clinical benefit that could accelerate adoption among nephrologists.
Commercial ExpansionExpanded label that includes pediatric patients and overlap with physicians treating IgA nephropathy, combined with a larger sales team and a stronger-than-expected IgA nephropathy launch, broadens the drug's commercial reach and uptake potential.
Regulatory ApprovalFDA approval of Filspari as the first therapy approved for focal segmental glomerulosclerosis without nephrotic syndrome validates efficacy in a defined patient subgroup and reduces regulatory uncertainty around proteinuria as an endpoint.
Bears Say
Clinical Efficacy UncertaintyMixed DUPLEX trial results and kidney function trends favoring irbesartan raise doubts about the drug's comparative benefit and could limit physician willingness to prescribe.
Label LimitationsInitial exclusion of patients with active nephrotic syndrome and variability in the supporting dataset shrink the immediate eligible population and introduce uncertainty about long-term treatment durability.
Pricing And Revenue PressureExpectations of larger gross-to-net discounts point to potential reductions in net product revenue, which could weigh on financial results even if demand increases.
Travere Therapeutics News
TVTX FAQ
What was Travere Therapeutics’s price range in the past 12 months?
Travere Therapeutics lowest stock price was $13.88 and its highest was $48.61 in the past 12 months.
What is Travere Therapeutics’s market cap?
Travere Therapeutics’s market cap is $3.97B.
When is Travere Therapeutics’s upcoming earnings report date?
Travere Therapeutics’s upcoming earnings report date is Jul 30, 2026 which is in 83 days.
How were Travere Therapeutics’s earnings last quarter?
Travere Therapeutics released its earnings results on May 04, 2026. The company reported -$0.4 earnings per share for the quarter, missing the consensus estimate of -$0.242 by -$0.158.
Is Travere Therapeutics overvalued?
According to Wall Street analysts Travere Therapeutics’s price is currently Undervalued.
Does Travere Therapeutics pay dividends?
Travere Therapeutics does not currently pay dividends.
What is Travere Therapeutics’s EPS estimate?
Travere Therapeutics’s EPS estimate is -0.05.
How many shares outstanding does Travere Therapeutics have?
Travere Therapeutics has 92,992,905 shares outstanding.
What happened to Travere Therapeutics’s price movement after its last earnings report?
Travere Therapeutics reported an EPS of -$0.4 in its last earnings report, missing expectations of -$0.242. Following the earnings report the stock price went down -0.245%.
Which hedge fund is a major shareholder of Travere Therapeutics?
Currently, no hedge funds are holding shares in TVTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Travere Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$53.42 (31.02% Upside)
$53.42 (31.02% Upside)
Blogger Sentiment
Bullish
TVTX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 1.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.8%
Last 30 Days ▲ 4.7%
Last 30 Days ▲ 4.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
173.25%
12-Months-Change
Fundamentals
Return on Equity
-79.16%
Trailing 12-Months
Asset Growth
1.86%
Trailing 12-Months
Company Description
Travere Therapeutics
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
TVTX Company Deck
TVTX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a strongly positive commercial and clinical momentum: a landmark FDA approval in FSGS, record demand and an 88% YoY increase in FILSPARI sales, encouraging pipeline progress (HARMONY restart with 2027 readout expectation), and improved non-GAAP profitability. Offsetting these positives are significant near-term cost increases (R&D and SG&A), higher royalty expense due to accounting changes, a continuing GAAP net loss, and some short-term revenue recognition/timing headwinds and education needs with physicians and payers. Overall, the positives (major approval, large sales growth, record demand, and clear runway to advance the pipeline) outweigh the near-term financial and operational challenges.View all TVTX earnings summariesTVTX Stock 12 Month Forecast
Average Price Target
$53.42
▲(31.02% Upside)
Technical Analysis
Galapagos
―
Arcutis Biotherapeutics
―
Disc Medicine
―
Tarsus Pharmaceuticals
―
Recursion Pharmaceuticals
―
Ownership Overview
1.57% Insiders
38.75% Mutual Funds
6.30% Other Institutional Investors
37.30% Public Companies and
Individual Investors